Clinical trials have shown promising results for interleukin-23 inhibitors in treating psoriasis. These drugs have been used in clinical practice since 2017.

The present study investigated the drug survival and effectiveness of interleukin-23 inhibitors in treating psoriasis and psoriatic arthritis (PsA) in a real-world setting.

It was a retrospective analysis of patients treated with either guselkumab, tildrakizumab, or risankizumab during the period from June 11, 2018, to July 14, 2021.

The study observed-

• Inclusion of 80 patients.
• Nineteen patients discontinued treatment with an interleukin-23 inhibitor.
• The mean treatment duration (SD) was 61.4 weeks (43.7).
• 95% previously used ≥1 biologic.
• One-year drug survival was 81.0%.
• 64.3% of patients achieved a Psoriasis Area and Severity Index (PASI) ≤ 2 at weeks 12–17; and 61.3% at weeks 40–60.
• No significant difference between the drugs regarding the chance of achieving PASI ≤ 2.
• Among 27.5% of patients demonstrating PsA, 40.9% and 36.4% achieved complete remission and partial remission, respectively.

This study shows that Interleukin-23 inhibitors have high and similar drug survival and effectiveness in patients with difficult-to-treat psoriasis and PsA.

Elgaard CDB, Iversen L, Hjuler KF. Guselkumab, tildrakizumab, and risankizumab in a real-world setting: drug survival and effectiveness in the treatment of psoriasis and psoriatic arthritis. Journal of Dermatological Treatment. 2022. DOI: 10.1080/09546634.2022.2133531